|
|
|
|
|
|
 |
| Ethos Endymion
Bright Eyes - Televised 6 Month Trail
|
| NAC (N-Acetyl-Carnosine)
Eye Drops
|
|
|
| |
| As Featured on "The Richard
& Judy Show" |
|
Lights, Cameras, Action...
As the set went quiet and the feature
opened with the three subjects attending
their preliminary eye examinations at
Optical Express in the Strand earlier
in the week to havetheir sight and cataracts
checked by another ophthalmic specialist |
|
before starting
their six months Ethos Endymion Bright Eyes trial
my heart missed a beat as I knew I'd be on live
TV any minute. They were each looked at individually
in turn and, after their examinations, the ophthalmologist
confirmed that all three had cataracts of varying
degrees of severity.
I was sat on the couch beside John Bolger, one
of the UK's leading BUPA cataract surgeons and
world authority on cataracts operations, and we
watched as they rolled a greatly speeded up clip
of John performing a cataracts operation while
he narrated, quickly explaining what exactly was
involved in the operation, and the different
steps he was doing as he completed them.
|
|
|
|
|
This part was definitely
not for the squeamish or faint-hearted
among the 2.1 million people viewing the
Show on Wednesday evening. I had never
seen one before myself, and can now quite
understand why Helen Aslam from Essex,
one of the two ladies out of the three trial
|
subjects, was so
traumatised by her first cataracts operation
that she refused to go in for surgery again to
have her other eye
|
done, and jumped at
the opportunity when her sister saw on
the C4 web site that they were looking
for people to try our revolutionary new
alternative treatment. |
|
We then discussed the Bright Eyes Treatment
and benefits with Richard and Judy and I think
everyone was a little taken aback by how open
John was to the new possibilities, and he even
commented at the end that he could possibly
see it replacing cataracts operations one day
in the future but he would wait to see the results
of the trial before commenting on it any further.
So a brilliant feature on National Television
and, as you can imagine, the calls have been
flooding into our offices with people wanting
to know more about Ethos Endymion Bright Eyes.
We would like to personally thank again Richard
and Judy for inviting us onto their show and
to Patrick Ruddy for his tireless efforts in
laying down all the groundwork and for organising
everything so professionally. And to all the
other people at Cactus TV who helped to make
it such a wonderful day for us.
We would also like to sincerely thank John
Bolger for being open-minded and for all his
help in researching Bright Eyes so that we could
initiate the trial in the first place - Thank
you John!
|
| |
| Bright Eyes Ingredients: |
| |
Antioxidants: N-Acetyl-Carnosine (NAC) - 1.0%
Glycerin (lubricant) - 1.0%
Hydroxypropylmethylcellulose Sodium (lubricant) - 0.15%
Sterile Water (ophthalmic grade isotonic solution, pH 6.3 to 6.5)
Buffered with Boric Acid, Citric Acid and Potassium Bicarbonate
And, as a preservative, Purified Benzyl Alcohol
|
| |
|
|
| Other Information: |
| |
Bright
Eyes is 100% hypoallergenic
Bright Eyes is 100% free of animal ingredients
and may be freely used by vegetarians
Bright Eyes is 100% safe and suitable for
use on pets and other animals
|
|
| |
| Bright Eyes Recommended Usage: |
| |
The
suggested use of Endymion Bright Eyes NAC
Eye Drops is to apply 1 to 2 drops in each
eye every day. Those with any kind of eye
problem may want to apply 1 to 2 drops several
times a day.
Each 5ml bottle should last 30 days at two drops per day or 15 days at four drops per day. A box contains 2 x 5ml bottles; therefore each package can last between 30 and 60 days which represents excellent value for money.
Unopened bottles should be stored in the dark in the refrigerator.
It is also recommended that you take 1 teaspoon
of Ethos élan vital supplement in powder form
daily.
|
|
|
Use
of Carnosine as an anti-senescence supplement |
|
From our
investigations, we have reported that eye drops
containing 20 mM carnosine were used to treat
96 patients aged 60 years old having senile cataract
of various degrees of maturity, with the duration
of the disease from 2 to 21 years. The method
is that after stopping all other anti-cataract
drugs, patients instilled 1-2 drops of the carnosine
containing solution in each eye 3-4 times each
day for a period of treatment ranging from 3-6
months. The level of eyesight improvement and
the change of lens transparency were considered
as an evaluation index of the curative effect
of carnosine.
The result
shows that carnosine gives a profound effect on
primary senile cataract, the effective rate being
100%.
For mature senile
cataract, the effect rate is 80%, and positive
effects were observed with other types of cataract.
It is significant
that no side effect has been found in the observed
cases. During recent years, we have also applied
carnosine drops containing the same content to
nearly 1,000 patients with senile cataract. Our
research findings (ready to be published) show
similar results.
In addition, we
applied carnosine drops to patients aged 48-60
years with various degrees of eyesight impairment
but without symptoms of cataract. The course of
treatment is from 2 to 6 months. The results demonstrate
that carnosine appears to alleviate eye tiredness
and comparatively improve eyesight (obviously
improve eyesight, giving more clear vision). Subjects
reported that carnosine could brighten and relax
their eyes.
It is an important
point that all the above research on the medical
application of carnosine has statistical significance.
|
|
| |
| Efficacy
of N-acetylcarnosine in the treatment of cataracts: |
Babizhayev
MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova
NG, Doroshenko VS, Zhukotskii AV, Goldman IM.
PURPOSE: To
evaluate the effects of 1% N-acetylcarnosine (NAC)
solution on lens clarity over 6 and 24 months
in patients with cataracts. TRIAL DESIGN: Randomised,
placebo-controlled study.
PARTICIPANTS:
49 subjects (76 affected eyes) with an average
age of 65.3 +/- 7.0 years with a diagnosis of
senile cataract with minimum to advanced opacification
in various lens layers. METHODS: 26 patients (41
eyes) were allocated to topical NAC 1% eyedrops
twice daily.
The control group consisted of
13 patients (21 eyes) who received placebo eyedrops
and 10 patients (14 eyes) who did not receive
eyedrops.
MAIN OUTCOME MEASURES:
All patients were evaluated at entry and followed
up every 2 months for a 6-month period (trial
1), or at 6-month intervals for a 2-year period
(trial 2), for best-corrected visual acuity and
glare testing. In addition, cataract was measured
using stereocinematographic slit-images and retro-illumination
examination of the lens. Digital analysis of lens
images displayed light scattering and absorbing
centres in two- and three-dimensional scales.
RESULTS: The
overall intra-reader reproducibility of cataract
measurements (image analysis) was 0.830, and glare
testing 0.998. After 6 months, 90% of NAC-treated
eyes showed improvement in best corrected visual
acuity (7 to 100%) and 88.9% showed a 27 to 100%
improvement in glare sensitivity.
Topographic studies indicated
fewer areas of posterior subcapsular lens opacity
and 41.5% of treated eyes had improvement in image
analysis characteristics. The overall ratios of
image analysis characteristics at 6 months compared
with baseline measures were 1.04 and 0.86 for
the control and NAC-treated group, respectively
(p < 0.001). The apparent benefits of treatment
were sustained after 24 months' treatment.
No treated eyes demonstrated
worsening of vision. The overall visual outcome
in the control group showed significant worsening
after 24 months in comparison with both baseline
and the 6-month follow-up examination. The overall
clinical results observed in the NAC-treated group
by the 24-month period of examination differed
significantly (p < 0.001) from the control
group in the eyes with cortical, posterior subcapsular,
nuclear or combined lens opacities. Tolerability
of NAC eyedrops was good in almost all patients,
with no reports of ocular or systemic adverse
effects.
CONCLUSION:
Topical NAC shows potential for the treatment
and prevention of cataracts.
Publication Types:
|
| |
Clinical Trial
Randomised Controlled Trial |
|
The
photographs below show images of a lens with senile
cataract (corticonuclear opacities, grade 4, age
75 years, female), and the subsequent slit images
in optical section documenting in the focal plane:
(a) marked light scattering in the nucleus and
posterior cortical region outlined by the lens
optical scanning with the focal plane movement
inside the lens thickness; (b) light scattering
in the anterior subcapsular, anterior cortical
and nuclear regions of the lens; retro-illumination
lens images with a focal plane positioned (c)
onto the iris and (d) on the posterior lens layers.
Opacities in the cortical layers are demonstrated
as the white background inclusions in the boundary
of the pupil locally masked by the flashlight
article. (e) the neutral density step reference
wedge captured in the plane of the camera focus
and allowing correction for variations in film
development and flashlight output.
|
 |
In
the NAC-treated group, 6-month follow-up showed
an improvement in VA (7-100%) in 37 of the 41
treated eyes and a significant improvement in
glare sensitivity at red and green targets (27-100%)
was documented in 16 of the 18 eyes tested. A
significant improvement in lens clarity was found
in 17 of the 41 eyes as documented by a significant
decrease of M and H characteristics during image
grading. The NAC-treated eyes had statistically
significant differences in VA, glare sensitivity
and characteristics of image analysis compared
with the control group (p < 0.001) at this
time point, as supported by the overall t-test
results of the ratio of the follow-up data to
the baseline values. |
|
|
|
| |
© The Ethos Group ∞ 2000-2010 ∞ All Rights Reserved ∞
|
|
|
USA Toll Free 
UK FREE PHONE 
Switzerland 
Holland 
Australia 
